On the stock market since 2017, it operates in the world of health and science. It has 155 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
There is $441.5M in the vault; even if every debt were paid off, $246.1M would remain.
The average analyst price target is $154 — 70% above today’s price.
A loss of $177.0M against $0 in annual sales.
At the current pace of spending, the cash lasts about 2.5 years. After that, the company needs to find new money.
On our five-subject report card, CELC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CELC is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (49/100) says the stock isn’t cheap.